FASN and breast carcinoma: In this study, we have investigated the anticancer activity of the classical FASN inhibitor epigallocathequin-3-gallate (EGCG) and G28UCM, as single agents or in combination with pertuzumab and temsirolimus, in our developed trastuzumab (SKTR), lapatinib (SKLR) and trastuzumab plus lapatinib (SKTLR) resistant HER2+ breast cancer models.